APSR2026-225

Yes
Late-Breaking
Submitted
Oral Presentation
AO06-003
 
 
https://storage.unitedwebnetwork.com/files/1285/1212517-46903-APSR2026-225_439787.pptx
Format: PPTX Only
 
Format: PDF Only
08. Lung Cancer
3

No more than 15 authors can be listed.
Please ensure the authors are listed in the right order.
If there are multiple affiliations, please use the "+" button next to "Select Country/Region" to add additional affiliation fields.

Lu Xu * Tianjin Medical University General Hospital Medical Oncology Department Tianjin China
Diansheng Zhong - Tianjin Medical University General Hospital Medical Oncology Department Tianjin China
Linlin Zhang - Tianjin Medical University General Hospital Medical Oncology Department Tianjin China
 
 
 
 
 
 
 
 
 
 
 
 
Presenting Author Details
Lu
Xu
X17647550138@163.com
+8617647550138
Under 30
China
Original Research
SLAMF1 Expression and Its Association with Immune Checkpoints in Non-Small Cell Lung Cancer
Maximum 25 words
Abstract Content
T细胞耗尽驱动非小细胞肺癌(NSCLC)中的肿瘤免疫逃避,其特征是共抑制受体持续表达。SLAMF1是一种免疫调节受体,但其在NSCLC肿瘤微环境中的作用及与T细胞耗尽的关联尚无明确。本研究探讨了SLAMF1与关键耗尽标记的相关性及其在枯竭CD8 T细胞亚组中的表达。+
通过癌症基因组图谱(TCGA)NSCLC队列进行转录组分析,评估SLAMF1与PDCD1(PD-1)、HAVCR2(TIM-3)、CTLA4、LAG3及TIGIT mRNA表达之间的相关性。为临床验证,从未治疗的晚期NSCLC患者中分离出外周血单核细胞(PBMCs)(n=39)。多参数流式细胞术用于量化CD8 T细胞的SLAMF1平均荧光强度(MFI),并采用配对t检验比较PD-1与PD-1及TIM-3与TIM-3亚组的表达。++-+-
在TCGA非小细胞肺癌组织中,SLAMF1 mRNA与所有五个耗尽标志物均呈显著正相关:TIGIT(r = 0.823,P = 6.19×10 -143),CTLA4(r = 0.749,P = 7.12×10-105), PDCD1 (r = 0.700, P = 4.91×10-86),LAG3 (r = 0.602,P = 4.32×10-58),以及HAVCR2(r = 0.583,P = 8.74×10-54).在患者外周血中,PD-1的SLAMF1 MFI显著升高于PD-1 CD8 T细胞(P = 0.0001)。同样,TIM-3 CD8 T细胞表现出比TIM-3对应细胞更高的SLAMF1 MFI(P < 0.0001)。+-+++-
SLAMF1是NSCLC中一种新型的耗尽标记,转录上与抑制性受体共表达,并选择性富集于耗尽的CD8 T细胞(PD-1/TIM-3),是逆转T细胞功能障碍的潜在靶点。+++
 
 
 
 
 
No
No
 
JPG or JPEG or PNG format ONLY
Non-small cell lung cancer, SLAMF1, T-cell exhaustion
maximum 3 keywords and no abbreviations, separated by commas
 
101